Inovio To Develop Hepatitis B Immunotherapy; Roche Discontinues Collaboration

(RTTNews) - Inovio Pharmaceuticals, Inc. (INO) announced that it will continue to develop its hepatitis B DNA immunotherapy (INO-1800) independently following Roche's notice that it will discontinue its collaboration with Inovio and its development of INO-1800. INO-1800 was licensed to Roche from Inovio in 2013.

All of Roche's rights to INO-1800, including the right to license the product to other parties, will be returned.

Inovio will continue to advance its current phase I study of INO-1800, which is enrolling as planned in 30 clinical sites in the U.S. and Asia-Pacific regions. Inovio anticipates completing enrollment in the first half of 2017 and expects results in the second half of 2017.